SecBot SecBot
SECBOTREPLAY Home › Report › NAMS

NAMS · Fidelity stake 10.0%

NewAmsterdam Pharma Co N.V. · SC 13G/A filed Nov 5, 2026 at 13:22 ET

At the news

NEUTRALIMPACT 2/10

SC 13G/A filed Nov 5, 2026 at 13:22 ET

FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 11,941,763 common shares of NewAmsterdam Pharma (NAMS) as of September 30, 2026, representing 10.0% of shares outstanding. This is an increase from the prior filing (August 2026) which reported 11,931,218 shares (10.0%), reflecting a net addition of approximately 10,545 shares. The filing remains a passive stake with no change in control intent.

  • FMR LLC (Fidelity) reported beneficial ownership of 11,941,763 shares of NewAmsterdam Pharma common stock as of September 30, 2026.
  • The stake represents 10.0% of the outstanding shares.
  • This is an increase of approximately 10,545 shares from the prior filing (11,931,218 shares as of June 30, 2026).
  • The filing is a passive Schedule 13G/A, indicating no intent to change or influence control of the issuer.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access